This HTML5 document contains 57 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n19http://localhost/temp/predkladatel/
n18http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n15http://linked.opendata.cz/resource/domain/vavai/subjekt/
n14http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n16http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n13http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F61989592%3A15110%2F13%3A33144214%21RIV14-MSM-15110___/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n6http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F61989592%3A15110%2F13%3A33144214%21RIV14-MSM-15110___
rdf:type
skos:Concept n14:Vysledek
dcterms:description
Avastin and Roferon in Renal Cell Carcinoma (AVOREN) demonstrated efficacy for bevacizumab plus interferon-alpha 2a (INF; 9 MIU tiw) in first-line metastatic renal cell carcinoma (mRCC). We evaluated bevacizumab with low-dose IFN mRCC to determine whether clinical benefit could be maintained with reduced toxicity. Avastin and Roferon in Renal Cell Carcinoma (AVOREN) demonstrated efficacy for bevacizumab plus interferon-alpha 2a (INF; 9 MIU tiw) in first-line metastatic renal cell carcinoma (mRCC). We evaluated bevacizumab with low-dose IFN mRCC to determine whether clinical benefit could be maintained with reduced toxicity.
dcterms:title
A multinational phase II trial of bevacizumab with low-dose interferon-alpha 2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN A multinational phase II trial of bevacizumab with low-dose interferon-alpha 2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN
skos:prefLabel
A multinational phase II trial of bevacizumab with low-dose interferon-alpha 2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN A multinational phase II trial of bevacizumab with low-dose interferon-alpha 2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN
skos:notation
RIV/61989592:15110/13:33144214!RIV14-MSM-15110___
n14:predkladatel
n15:orjk%3A15110
n3:aktivita
n12:S
n3:aktivity
S
n3:cisloPeriodika
9
n3:dodaniDat
n6:2014
n3:domaciTvurceVysledku
n18:5290791
n3:druhVysledku
n10:J
n3:duvernostUdaju
n17:S
n3:entitaPredkladatele
n13:predkladatel
n3:idSjednocenehoVysledku
58774
n3:idVysledku
RIV/61989592:15110/13:33144214
n3:jazykVysledku
n11:eng
n3:klicovaSlova
VEGF; interferon; immunotherapy; bevacizumab; angiogenesis; renal cell carcinoma
n3:klicoveSlovo
n8:renal%20cell%20carcinoma n8:angiogenesis n8:VEGF n8:immunotherapy n8:bevacizumab n8:interferon
n3:kodStatuVydavatele
GB - Spojené království Velké Británie a Severního Irska
n3:kontrolniKodProRIV
[7AC871651291]
n3:nazevZdroje
Annals of Oncology
n3:obor
n7:FD
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
17
n3:rokUplatneniVysledku
n6:2013
n3:svazekPeriodika
24
n3:tvurceVysledku
Magne, N. Mickisch, G. Bracarda, S. Osborne, S. Ivanov, S. Fernebro, E. Bellmunt, J. Gore, M. Melichar, Bohuslav Moorselaar, R. Staehler, M. Matveev, V. Jethwa, S. Mulders, P. Zyryanov, A. Alekseev, B. Janciauskiene, R.
s:issn
0923-7534
s:numberOfPages
7
n16:doi
10.1093/annonc/mdt228
n19:organizacniJednotka
15110